CA2229786C - Formes zwitterioniques de trovafloxacine - Google Patents

Formes zwitterioniques de trovafloxacine Download PDF

Info

Publication number
CA2229786C
CA2229786C CA002229786A CA2229786A CA2229786C CA 2229786 C CA2229786 C CA 2229786C CA 002229786 A CA002229786 A CA 002229786A CA 2229786 A CA2229786 A CA 2229786A CA 2229786 C CA2229786 C CA 2229786C
Authority
CA
Canada
Prior art keywords
compound
hygroscopic
polymorph
formula
pentahydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002229786A
Other languages
English (en)
Other versions
CA2229786A1 (fr
Inventor
David Bruning Joseph
Douglas John Meldrum Allen
Timothy Norris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CA2229786A1 publication Critical patent/CA2229786A1/fr
Application granted granted Critical
Publication of CA2229786C publication Critical patent/CA2229786C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Physical Water Treatments (AREA)
  • Processing Of Solid Wastes (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

On décrit une forme zwittérionique de trovafloxacine possédant la formule (I) et choisie dans le groupe constitué par des polymorphes cristallins de celle-ci, hygroscopiques et non hygroscopiques, et par un pentahydrate de celle-ci. On décrit également des procédés de préparation de ces composés, des procédés d'utilisation de ceux-ci, ainsi que des compositions pharmaceutiques contenant ces composés et servant au traitement d'infections bactériennes chez les mammifères.
CA002229786A 1995-08-29 1996-07-29 Formes zwitterioniques de trovafloxacine Expired - Fee Related CA2229786C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US297595P 1995-08-29 1995-08-29
US60/002,975 1995-08-29
PCT/IB1996/000756 WO1997007800A1 (fr) 1995-08-29 1996-07-29 Formes zwitterioniques de trovafloxacine

Publications (2)

Publication Number Publication Date
CA2229786A1 CA2229786A1 (fr) 1997-03-06
CA2229786C true CA2229786C (fr) 2002-02-19

Family

ID=21703460

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002229786A Expired - Fee Related CA2229786C (fr) 1995-08-29 1996-07-29 Formes zwitterioniques de trovafloxacine

Country Status (30)

Country Link
EP (1) EP0850060A1 (fr)
JP (1) JP3188476B2 (fr)
KR (1) KR100343909B1 (fr)
CN (1) CN1190889A (fr)
AP (1) AP636A (fr)
AR (1) AR003985A1 (fr)
AU (1) AU704115B2 (fr)
BR (1) BR9609998A (fr)
CA (1) CA2229786C (fr)
CO (1) CO4480739A1 (fr)
CZ (1) CZ56698A3 (fr)
DZ (1) DZ2087A1 (fr)
GT (1) GT199600072A (fr)
HR (1) HRP960395B1 (fr)
HU (1) HUP9900170A3 (fr)
IL (1) IL122651A (fr)
MA (1) MA23966A1 (fr)
MY (1) MY113874A (fr)
NO (1) NO309814B1 (fr)
NZ (1) NZ312199A (fr)
OA (1) OA10669A (fr)
PE (1) PE12598A1 (fr)
PL (1) PL325170A1 (fr)
RU (1) RU2144921C1 (fr)
SK (1) SK23898A3 (fr)
TN (1) TNSN96109A1 (fr)
TR (1) TR199800339T1 (fr)
WO (1) WO1997007800A1 (fr)
YU (1) YU48396A (fr)
ZA (1) ZA967282B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1998000106A (es) 1997-08-01 1999-01-08 Pfizer Prod Inc Composiciones parenterales de alatroflaxacino
US7019142B2 (en) 1998-01-16 2006-03-28 Pfizer Inc. Process for preparing naphthyridones and intermediates
PA8466701A1 (es) * 1998-01-21 2000-09-29 Pfizer Prod Inc Comprimido de mesilato de trovafloxacino
US6114531A (en) * 1998-07-28 2000-09-05 Pfizer Inc. Process for preparing quinolone and naphthyridone carboxylic acids
HN1999000141A (es) * 1998-09-03 2000-06-19 Pfizer Prod Inc Procedimiento para preparar sales de trovafloxacina de adicion de acidos.
US6239141B1 (en) * 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164402A (en) * 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids

Also Published As

Publication number Publication date
NO980862L (no) 1998-02-27
TNSN96109A1 (fr) 2005-03-15
HUP9900170A2 (hu) 1999-05-28
JPH10511692A (ja) 1998-11-10
IL122651A0 (en) 1998-08-16
NZ312199A (en) 1999-06-29
EP0850060A1 (fr) 1998-07-01
NO980862D0 (no) 1998-02-27
BR9609998A (pt) 1999-07-06
AP636A (en) 1998-04-09
AU6367696A (en) 1997-03-19
PL325170A1 (en) 1998-07-06
AU704115B2 (en) 1999-04-15
ZA967282B (en) 1998-03-02
CA2229786A1 (fr) 1997-03-06
HRP960395B1 (en) 2001-12-31
MY113874A (en) 2002-06-29
HUP9900170A3 (en) 1999-11-29
JP3188476B2 (ja) 2001-07-16
MX9801664A (es) 1998-08-30
OA10669A (en) 2000-11-06
KR100343909B1 (ko) 2003-04-10
DZ2087A1 (fr) 2002-07-22
CZ56698A3 (cs) 1999-02-17
GT199600072A (es) 1998-02-14
AR003985A1 (es) 1998-09-30
HRP960395A2 (en) 1998-06-30
MA23966A1 (fr) 1997-04-01
IL122651A (en) 2000-02-17
WO1997007800A1 (fr) 1997-03-06
CO4480739A1 (es) 1997-07-09
AP9600853A0 (en) 1996-10-31
PE12598A1 (es) 1998-03-20
YU48396A (sh) 1998-12-23
RU2144921C1 (ru) 2000-01-27
SK23898A3 (en) 1999-05-07
CN1190889A (zh) 1998-08-19
NO309814B1 (no) 2001-04-02
KR19990044232A (ko) 1999-06-25
TR199800339T1 (xx) 1998-06-22

Similar Documents

Publication Publication Date Title
US5763454A (en) Crystal form of anhydrous 7-( 1α,5α,6α!-6-amino-3-azabicyclo 3.1.0!hex-3-yl)-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8 naphthyridine-3-carboxylic acid, methanessulfonic acid salt
CA2229786C (fr) Formes zwitterioniques de trovafloxacine
US6066647A (en) Zwitterionic forms of trovafloxacin
EP0847400B1 (fr) Polymorphes du promedicament 6-n-(l-ala-l-ala)-trovafloxacine
NZ260158A (en) N-benzyl piperazine derivatives, preparation and pharmaceutical compositions thereof
MXPA98001664A (en) Zwitterionic forms of trovafloxacin, procedure for its preparation, compositions that contain them and use of the mis
AP788A (en) Novel crystal form of anhydrous 7-(1a, 5a, 6a)-6-Amino-3-Azabicyclo(3.1.0) hex-3-YI)-6-Fluoro-1-(2,4- Difluorophenyl)-1,4-Dihydro-4-Oxo-1, 8-Naphthyridine-3-Carboxylic Acid, Methanesulfonic acid salt.
US5331010A (en) 1-phenylalkanecarboxylic acid derivatives as anticonvulsant and neuroprotective agents
CA2258960C (fr) Procede de preparation de naphtyridones et de leurs intermediaires
BG60536B2 (bg) Производни на тиазолидинона,фармацевтични състави които ги съдържат и метод за получаването им
MXPA98001665A (en) Polymorphoses of profarmaco of 6-n- (l-ala-l-ala) -trovafloxacin, procedure for its preparation and use of mis

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed